Early malaria vaccine trial halted – what we know
NCT ID NCT05270265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new vaccine against Plasmodium vivax malaria, given with an adjuvant to boost immune response. It involved 25 healthy adults in the UK to check safety and immune reactions. The study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pvs25-IMX313 vaccine with Matrix-M1 adjuvant
What this could lead to
If successful, this could help develop a vaccine against Plasmodium vivax malaria, a major cause of malaria outside Africa.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so results are limited. The vaccine may not produce strong enough immunity or may have safety issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA VIVAX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CCVTM, University of Oxford, Churchill Hospital
Oxford, OX3 7LE, United Kingdom